Slide 1: Q1 2021 Sales Update
Diana Living with post-stroke spasticity Sintra, Portugal Q1 2021 Sales Update 22 April 2021 1
Slide 2: Disclaimer & Safe Harbor
Disclaimer & Safe Harbor • This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements
Slide 3: Speakers
Speakers David Loew Aymeric Le Chatelier Chief Executive Officer Chief Financial Officer (for Q&A) 3
Slide 4: Q1 2021 Encouraging top-line and pipeline progress
Q1 2021 Encouraging top-line and pipeline progress Key highlights Total Sales +5.5% to €659m Regulatory EU approval • Specialty Care +6.4% to €612m • Cabometyx + nivolumab in 1L aRCC COVID-19 Near term • Limiting diagnoses, treatments and • Cabometyx 1L HCC data readout patient care • Palovarotene r
Slide 5: Q1 2021 sales highlights
Q1 2021 sales highlights Oncology COVID-19 +4.9% limiting diagnoses and treatments €495m: 75% of Total Sales +2.5%, driven by North America (+5.1%) +4.9% €m Some stocking in Europe in Q1 2020 31 26 Continued share growth 72 83 +12.0%, driven by recovery in China 97 106 Gaining market share Focusing
Slide 6: Q1 2021 sales highlights
Q1 2021 sales highlights Consumer Healthcare +18.9% -5.4% €102m: 15% of Total Sales €47m: 7% of Total Sales +18.9% -5.4% €m • Aesthetics driving the €m • Smecta -4.9%, driven by 7 6 Other performance the slowdown of the 7 diarrhea market 7 Fortrans/ • Therapeutics and Europe overall 10 Eziclen 9 sti
Slide 7: Pipeline
Pipeline Phase I Phase II Phase III Registration Cabometyx + atezolizumab IPN60130 Cabometyx + atezolizumab Dysport solution Solid tumors FOP1 1L HCC Glabellar lines IPN59011 Cabometyx + atezolizumab Dysport Longer-acting neurotoxin 2L NSCLC NDO2 Ax IPN10200 Cabometyx + atezolizumab Longer-acting ne
Slide 8: FY 2021 guidance confirmed
FY 2021 guidance confirmed Sales growth • Expected FY 2021 adverse currency impact of 2%, based on exchange rates at the end of Q1 > +4.0% at CER 2021 Core Operating margin • Excluding any potential impact of incremental investments from external innovation > 30.0% of Total Sales Key assumptions: −
Slide 9: Focus. Together. For patients & society
Focus. Together. For patients & society Maximize Strengthen our brands pipeline Drive Focus on efficiencies culture 9
Slide 10: Q&A
Q&A Ronny Living with neuroendocrine tumors Ringwood, UK 10
Slide 11: APPENDIX
APPENDIX 11
Slide 12: Q1 2021 sales growth driven by Specialty Care
Q1 2021 sales growth driven by Specialty Care Specialty Care Consumer Healthcare Total Sales: €612m Total Sales: €47m €m +6.4% €m -5.4% +2.5% -4.9% Specialty Care €2,381.1m +5.9%1 -5.6% 277 -10.0% +12.0% +18.9% 16 +6.1% +16.4% -10.6% Consumer Healthcare 9 106 102 83 -6.9% 9 €210.6m 7 6 -23.9% -9.7%
Slide 13: Oncology
Oncology Key ongoing clinical-trial highlights Trial Population Patients Design Endpoints Status Sorafenib Cabometyx Recruiting or Primary: PFS, OS COSMIC 312 1L HCC 740 Cabometyx + atezolizumab Secondary: PFS single-agent Phase III Data anticipated or Cabometyx arm NCT03755791 Q2 2021 Cabometyx Cab
Slide 14: Oncology
Oncology Key ongoing clinical-trial highlights Trial Population Patients Design Endpoints Status Onivyde Nab-paclitaxel + gemcitabine Recruiting NAPOLI 3 or Primary: OS 1L PDAC 750 Phase III Onivyde + 5-FU/LV + Secondary: PFS, ORR, safety Data anticipated NCT04083235 oxaliplatin 2023 Onivyde Active,
Slide 15: Neuroscience
Neuroscience Key ongoing clinical-trial highlights Trial Population Patients Design Endpoints Status IPN59011 Ax Moderate to LONG-SET Dose escalation and dose finding Primary: Safety severe upper 424 Recruiting Phase I versus Dysport or placebo Secondary: Efficacy facial lines NCT04736745 IPN10200 A
Slide 16: Rare Disease
Rare Disease Key ongoing clinical-trial highlights Trial Population Patients Design Endpoints Status Primary: annualized change in Palovarotene Palovarotene - 5mg QD and new HO volume MOVE FOP upon flare-up, 20mg QD for Secondary: subjects with new 107 Active, not recruiting Phase III (chronic) 28 d